Xi Liu
Founder en BEIJING STRONG BIOTECHNOLOGIES,INC. .
Fortuna: 193 M $ al 29/02/2024
Perfil
Xi Liu founded Beijing Strong Biotechnologies, Inc. Dr. Liu is General Manager & Director at this company.
Dr. Liu is also on the board of Fuzhou Maixin Biotech Co., Ltd.
He received a graduate degree from Harbin Engineering University and a doctorate from Institute of Automation Chinese Academy of Sciences.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
30/06/2023 | 50 260 257 ( 19.76% ) | 145 M $ | 29/02/2024 | |
30/06/2023 | 16 753 419 ( 5.01% ) | 48 M $ | 29/02/2024 |
Cargos activos de Xi Liu
Empresas | Cargo | Inicio |
---|---|---|
BEIJING STRONG BIOTECHNOLOGIES,INC. | Founder | 29/03/2001 |
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Director/Board Member | 30/09/2020 |
Formación de Xi Liu.
Harbin Engineering University | Graduate Degree |
Institute of Automation Chinese Academy of Sciences | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BEIJING STRONG BIOTECHNOLOGIES,INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Health Services |